Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21292655 | 0.98 | CRBN (0.37) | CRBNDDB1BACE1NEK2PDE7A | |
| Hydrochloric Acid SCHEMBL31733116 | 0.98 | CRBN (0.37) | CRBNDDB1BACE1NEK2PDE7A | |
| SCHEMBL24535197 | 0.88 | PDE7A (0.38) | CRBNPDE7A | |
| SCHEMBL3332022 | 0.88 | PDE7A (0.38) | CRBNPDE7A | |
| SCHEMBL239415 | 0.86 | CRBN (0.41) | CRBNDDB1NEK2PDE7A | |
| SCHEMBL29680096 | 0.86 | PDE7A (0.39) | CRBNPDE7A | |
| Ammonia Solution, Strong SCHEMBL1763719 | 0.84 | CRBN (0.40) | CRBNDDB1NEK2PDE7A | |
| Hydrochloric Acid SCHEMBL8809373 | 0.84 | CRBN (0.40) | CRBNDDB1NEK2PDE7A | |
| SCHEMBL435304 | 0.81 | CRBN (0.36) | CRBNDDB1PDE7A | |
| SCHEMBL23651601 | 0.79 | PDE7A (0.38) | CRBNNEK2PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-119751465-A | Spiro compounds | C4医药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118084940-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4227302-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20160318870-A1 | RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| EP-3044219-A1 | RORGAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9120804-B2 | 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| WO-2015035278-A1 | RORγ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7192967-B1 | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents | ASTELLAS PHARMA GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885BACE1 1046/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885BACE1 1979/4885 |
| US-20160318870-A1 | RORy MODULATORS | RORB, RORC, RORA | CRBN 699/4885DDB1 3926/4885BACE1 660/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885BACE1 1046/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CRBN 1103/4885DDB1 83/4885BACE1 1046/4885 |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | SYK, EIF2AK4, BTK | CRBN 630/4885DDB1 2023/4885BACE1 4198/4885 |
| US-11623929-B2 | Spirocyclic compounds | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885BACE1 1979/4885 |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | CRBN 3667/4885DDB1 1983/4885BACE1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.